207 related articles for article (PubMed ID: 17308317)
1. Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.
Jin HM; Pan Y
Nephrol Dial Transplant; 2007 Jul; 22(7):1943-9. PubMed ID: 17308317
[TBL] [Abstract][Full Text] [Related]
2. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Guo LL; Pan Y; Jin HM
Nephrol Dial Transplant; 2009 Jun; 24(6):1876-83. PubMed ID: 19164322
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
[TBL] [Abstract][Full Text] [Related]
4. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Aksnes TA; Reims HM; Guptha S; Moan A; Os I; Kjeldsen SE
J Hum Hypertens; 2006 Nov; 20(11):860-6. PubMed ID: 16988754
[TBL] [Abstract][Full Text] [Related]
5. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Abe H; Minatoguchi S; Ohashi H; Murata I; Minagawa T; Okuma T; Yokoyama H; Takatsu H; Takaya T; Nagano T; Osumi Y; Kakami M; Tsukamoto T; Tanaka T; Hiei K; Fujiwara H
Hypertens Res; 2007 Oct; 30(10):929-35. PubMed ID: 18049024
[TBL] [Abstract][Full Text] [Related]
6. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
7. Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without β-blockers.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Kaetsu Y; Mizuta E; Sugihara S; Ishida K; Yanagihara K; Hisatome I; Shigemasa C
Circ J; 2010 Nov; 74(11):2346-52. PubMed ID: 20827028
[TBL] [Abstract][Full Text] [Related]
8. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.
Praga M; Andrade CF; Luño J; Arias M; Poveda R; Mora J; Prat MV; Rivera F; Galceran JM; Ara JM; Aguirre R; Bernis C; Marín R; Campistol JM
Nephrol Dial Transplant; 2003 Sep; 18(9):1806-13. PubMed ID: 12937228
[TBL] [Abstract][Full Text] [Related]
9. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y
Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Derosa G; Querci F; Franzetti I; Dario Ragonesi P; D'Angelo A; Maffioli P
Hypertens Res; 2015 Oct; 38(10):690-4. PubMed ID: 25994603
[TBL] [Abstract][Full Text] [Related]
11. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
12. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Ruilope LM; Segura J
Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, controlled study of losartan in children with proteinuria.
Webb NJ; Lam C; Loeys T; Shahinfar S; Strehlau J; Wells TG; Santoro E; Manas D; Gleim GW
Clin J Am Soc Nephrol; 2010 Mar; 5(3):417-24. PubMed ID: 20089489
[TBL] [Abstract][Full Text] [Related]
14. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Daikuhara H; Kikuchi F; Ishida T
Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
Yilmaz MI; Carrero JJ; Martín-Ventura JL; Sonmez A; Saglam M; Celik T; Yaman H; Yenicesu M; Eyileten T; Moreno JA; Egido J; Blanco-Colio LM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1174-81. PubMed ID: 20430947
[TBL] [Abstract][Full Text] [Related]
16. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
Masuda S; Tamura K; Wakui H; Kanaoka T; Ohsawa M; Maeda A; Dejima T; Yanagi M; Azuma K; Umemura S
Hypertens Res; 2009 Nov; 32(11):950-5. PubMed ID: 19713965
[TBL] [Abstract][Full Text] [Related]
17. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
Bichu P; Nistala R; Khan A; Sowers JR; Whaley-Connell A
Vasc Health Risk Manag; 2009; 5(1):129-40. PubMed ID: 19436679
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacogenetics of angiotensin system in non diabetic nephropathy].
Coto E; Marín R; Alvarez V; Praga M; Fernández Andrade C; Arias M; Poveda R; Vallés M; Galcerán JM; Luño J; Rivera F; Campistol JM
Nefrologia; 2005; 25(4):381-6. PubMed ID: 16231503
[TBL] [Abstract][Full Text] [Related]
20. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension.
Watanabe S; Okura T; Kurata M; Irita J; Manabe S; Miyoshi K; Fukuoka T; Murakami K; Higaki J
Clin Ther; 2006 Oct; 28(10):1677-85. PubMed ID: 17157123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
